Paper
The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro.
Published Feb 1, 2002 · A. Taranta, M. Brama, M. Brama
Bone
Q1 SJR score
167
Citations
9
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
In Vitro Study
Highly CitedStudy Snapshot
Raloxifene reduces osteoclast activity and stimulates osteoblast activity in vitro, suggesting both an antiresorptive and osteoblast stimulatory role in osteoporosis treatment.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...
References
Expression and regulation of Runx2/Cbfa1 and osteoblast phenotypic markers during the growth and differentiation of human osteoblasts *
In committed human osteoblasts, constitutive expression of Cbfa1 may be required to sustain the osteoblast phenotype, with multiple levels of regulation in this process.
2001·191citations·Michelle Prince et al.·Journal of Cellular Biochemistry
Journal of Cellular Biochemistry
Melanoma cells stimulate osteoclastogenesis, c-Src expression and osteoblast cytokines.
Melanoma cells stimulate osteoclastogenesis through a paracrine mechanism, specifically upregulating c-Src in osteoclasts and cytokine expression in osteoblasts.
2001·25citations·Marie Perez et al.·European journal of cancer
European journal of cancer
Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression.
Estrogens suppress osteoclast formation by down-regulating osteoclastogenic cytokines and directly suppressing RANKL-induced osteoclast differentiation, potentially preventing osteoporosis.
2000·488citations·N. Shevde et al.·Proceedings of the National Academy of Sciences of the United States of America
Proceedings of the National Academy of Sciences of the United States of America
Transient estrogen exposure of female mice during early development permanently affects osteoclastogenesis in adulthood.
Transient estrogen exposure during early development in female mice permanently affects osteoclastogenesis in adulthood, potentially playing a role in bone-cell imprinting during early bone development.
2000·38citations·S. Migliaccio et al.·Bone
Bone
Behavioral effects of prenatal versus postnatal androgen excess in children with 21-hydroxylase-deficient congenital adrenal hyperplasia.
High levels of androgens during fetal development contribute to behavioral masculinization in girls with CAH, rather than postnatal life.
2000·149citations·S. Berenbaum et al.·The Journal of clinical endocrinology and metabolism
The Journal of clinical endocrinology and metabolism
Citations
Real-world study of medication-related osteonecrosis of the jaw from 2010 to 2023 based on Food and Drug Administration’s adverse event reporting system
Bisphosphonate, RANKL inhibitor, and radiotherapy drugs are associated with a higher risk of medication-related osteonecrosis of the jaw, with females having a higher incidence than males.
2025·0citations·Yuhao Zhong et al.·JBMR Plus
JBMR Plus
Effect of co-loaded vitamin D3 on intravenous injectable raloxifene delivery system.
Co-encapsulating raloxifene and vitamin D3 in HSA-based nanoparticles improves their bioavailability, compatibility, and residence time in the body, making them a potential nanomedicine contender for treating postmenopausal osteoporosis.
2024·0citations·Chih-Hao Chang et al.·Colloids and surfaces. B, Biointerfaces
Colloids and surfaces. B, Biointerfaces
Periodontal medicine: The bidirectional relationship between osteoporosis and periodontal health
Osteoporosis and periodontitis have a mutual effect and may be risk factors for each other, necessitating concurrent therapy and interdisciplinary approaches to prevention and care.
2024·0citations·Shivani Sachdeva et al.·Journal of Cellular Biotechnology
Journal of Cellular Biotechnology
Osteoporosis treatments for intervertebral disc degeneration and back pain: a perspective
Osteoporosis treatments like bisphosphonates and denosumab may also relieve low back pain by targeting intervertebral disc degeneration.
2024·0citations·Neharika Bhadouria et al.·JBMR Plus
JBMR Plus
Combining anabolic loading and raloxifene improves bone quantity and some quality measures in a mouse model of osteogenesis imperfecta.
Combining raloxifene and loading improves bone quantity and some quality measures in a mouse model of osteogenesis imperfecta, with subtle changes in bone quality.
2024·2citations·Amy E Creecy et al.·Bone
Bone
Osteoimmunology: The Crosstalk between T Cells, B Cells, and Osteoclasts in Rheumatoid Arthritis
Understanding the connection between the immune system and osteoclasts in rheumatoid arthritis can improve early diagnosis, treatment, and prognosis of this condition.
2024·10citations·Mei Yang et al.·International Journal of Molecular Sciences
International Journal of Molecular Sciences
Injectable hydrogel scaffolds composed of Nanocellulose derived from sugarcane bagasse and combined with calcium for Bone regeneration
Ca-IHS4, a formulation of nanocellulose from sugarcane bagasse and calcium, offers a simple, safe, and non-invasive platform for bone regeneration.
2023·4citations·R. Kamel et al.·Research Journal of Pharmacy and Technology
Research Journal of Pharmacy and Technology